Theragen Etex Co.,Ltd. announced that it expects to receive KRW 20 billion in funding
October 22, 2018
Share
Theragen Etex Co.,Ltd. (KOSDAQ:A066700) announced a private placement of 8th series unregistered unguaranteed convertible bonds for gross proceeds of KRW 20,000,000,000 on October 23, 2018. The bond is issued at 0% coupon rate and 1% yield to maturity rate. The bonds can be 100% converted into 1,574,803 common shares of the company representing 5.11% of the total number of stocks at a fixed conversion price of KRW 12,700 per share. The conversion period is from October 25, 2019 to September 25, 2022. The transaction will involve participation from Platform Partners Smart Mezzanine 4.0 Hedge Fund 4, Platform Partners Smart Mezzanine 4.0 Hedge Fund 5, Platform Partners Smart Mezzanine 4.0 Hedge Fund 7, The Plaform Multi-strategy Hedge Fund 1, The Plaform Multi-strategy Hedge Fund 2, The Plaform Project Mezzanine Hedge Fund 1 for KRW 9,000,000,000, KB securities corporation for KRW 1,000,000,000, Mirae Asset treatment corporation for KRW 9,000,000,000, and Daeha Heang for KRW 1,000,000,000. The transaction has been approved by the board of directors of the company. The payment date of the transaction is October 25, 2018.
THERAGEN ETEX CO.LTD. is a Korea-based company engaged in the industrial equipment business, healthcare and genome business and pharmaceutical business. The Company operates its business through three divisions: flat panel display (FPD) manufacturing equipment division, which provides loading and unloading systems, printed circuit board (PCB) bonding systems, battery washing lines and laser systems; healthcare and genome division engages in the provision of genome analysis services and others, and pharmaceutical division engages in the manufacture of digestive system remedies, antibiotics, remedies for fever, circulatory system remedies, respiration system remedies, treatment for chronic hepatitis, diabetes remedies, psychotropic agents, osteoporosis treatments and others.